NCT00981318

Pilot Assessment of Lopinavir/Ritonavir and Maraviroc

Pilot Assessment of Lopinavir/Ritonavir and Maraviroc in Experienced Patients

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Rodwick, Barry M., M.D. · Individual
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a study to assess the response of lopinavir/ritonavir plus maraviroc (with no nucleoside medications) in HIV patients failing their initial antiviral therapy.

Detailed description

As long-term toxicity to many of the nucleoside medications have become known, interest has increased in treatment regimens that do not use these medications. This study is to assess the response of one such "nucleoside-sparing" therapy in patients who are showing failure to their initial nucleoside-containing treatment regimen.

Conditions

• HIV Infections
• Acquired Immunodeficiency Syndrome

Interventions

Type	Name	Description
DRUG	lopinavir/ritonavir plus maraviroc	lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid

Timeline

• Start date: 2009-12-01
• Primary completion: 2015-05-01
• Completion: 2015-05-01
• First posted: 2009-09-22
• Last updated: 2015-06-23

Locations

1 site across 1 country: United States